{"success":true,"data":{"pressRelease":{"id":"34233","rtpr_id":"nGNX6P0Xkm","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law","author":"Globe Newswire","published_at":"2026-05-13T21:20:00.094Z","article_body":"SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller\nRudman & Dowd LLP\n(https://www.globenewswire.com/Tracker?data=dH1JBRVVUwAtXSs_rPieSwPWzxJF0xTeZdxEGs6TGiSetSaiExM7CfQxYu6Z0lNy1coB2W9KDuPmK_EgJEZ4KYbdNqTIRqvFIRvVE5vrIxE3Jp9F-MKSHSV45WLVtynIcC5LciJ8UV-BIJcXgEO3OaMY2cd0tij7xo9cjjtVEqj2H2NtQfSHFtQQvMWvFkq9)\nannounces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX)\npublicly traded securities between January 19, 2026 and March 24, 2026,\ninclusive (the “Class Period”), have until Tuesday, May 26, 2026 to seek\nappointment as lead plaintiff of the ImmunityBio class action lawsuit.\nCaptioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the\nImmunityBio class action lawsuit charges ImmunityBio as well as\nImmunityBio’s Executive Chairman with violations of the Securities Exchange\nAct of 1934.\n\nIf you suffered substantial losses and wish to serve as lead plaintiff of the\nImmunityBio class action lawsuit, please provide your information here:\n\nhttps://www.rgrdlaw.com/cases-immunitybio-class-action-lawsuit-ibrx.html\n\nYou can also contact attorneys Ken Dolitsky\n(https://www.globenewswire.com/Tracker?data=EVww4Y5UFsL1vs19Fy70IcpzR5gCXOPQ535hSYzguF7a7oyvurjj8iSQPGt4EEZSPBevfHgaDa-lhV2OxwS0ZlDN7yx1jCrT64PJkk64F-FjUohH8ShZUTVlGHUwLP0o-g7SYCSWfnNxQMQRes0glw==)\nor Michael Albert\n(https://www.globenewswire.com/Tracker?data=Za-Unon5XnbaPUaFcgReWsS9fZEYvbMC8lgSbInQbBYb7WnRkABDXC_1g5eua0uBdgnDovZeCJ8aVMnfTETPAvAQSnNBEIo5TGDaPUB5Snqo_4RDvpzmKt1dDOnAFIELSIsGUWVq9knAuNlB2-OvNwuT81XvHMTYrXxhrIyk9LI=)\nof Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.\n\nCASE ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on\ninnovating, developing, and commercializing next-generation immunotherapies.\nAccording to the complaint, ImmunityBio’s lead biologics product is Anktiva.\n\nThe ImmunityBio class action lawsuit alleges that defendants throughout the\nClass Period made false and/or misleading statements and/or failed to disclose\nthat: (i) representations that “Anktiva will allow all NMIBC patients\ntreated with Anktiva to be cancer-free for the long term, when this has not\nbeen demonstrated”; (ii) the claim that Anktiva is a cancer vaccine was\nfalse; and (iii) ImmunityBio’s Executive Chairman and Global Scientific and\nMedical Officer, defendant Dr. Patrick Soon-Shion, materially overstated\nAnktiva’s capabilities.\n\nThe ImmunityBio class action lawsuit further alleges that on March 24, 2026, a\nwarning letter (dated March 13, 2026) from the U.S. Food and Drug\nAdministration to CEO Richard Adcock was publicized, stating that a “TV ad\nand podcast misbrand[ed] Anktiva and make the distribution of the drug in\nviolation of the Federal Food, Drug, and Cosmetic Act.” The warning letter\nallegedly further stated that “[t]hese violations are concerning from a\npublic health perspective because the promotional communications create a\nmisleading impression that Anktiva, a treatment for a certain type of bladder\ncancer, can cure and even prevent all cancer.” On this news, the price of\nImmunityBio stock fell 21%, according to the complaint.\n\nTHE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of\n1995 permits any investor who purchased or acquired ImmunityBio publicly\ntraded securities during the Class Period to seek appointment as lead\nplaintiff in the ImmunityBio class action lawsuit. A lead plaintiff is\ngenerally the movant with the greatest financial interest in the relief sought\nby the putative class who is also typical and adequate of the putative class.\nA lead plaintiff acts on behalf of all other class members in directing the\nImmunityBio investor class action lawsuit. The lead plaintiff can select a law\nfirm of its choice to litigate the ImmunityBio shareholder class action\nlawsuit. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff of the ImmunityBio class action\nlawsuit.\n\nABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s\nleading law firms representing investors in securities fraud and shareholder\nrights litigation. Our Firm ranked #1 on the most recent ISS Securities Class\nAction Services Top 50 Report, recovering more than $916 million for investors\nin 2025. This marks our fourth #1 ranking in the past five years. And in those\nfive years alone, Robbins Geller recovered $8.4 billion for investors – $3.4\nbillion more than any other law firm. With 200 lawyers in 10 offices, Robbins\nGeller is one of the largest plaintiffs’ firms in the world, and the\nFirm’s attorneys have obtained many of the largest securities class action\nrecoveries in history, including the largest ever – $7.2 billion – in In\nre Enron Corp. Sec. Litig. Please visit the following page for more\ninformation:\n\nhttps://www.rgrdlaw.com/services-litigation-securities-fraud.html\n\nPast results do not guarantee future outcomes. \nServices may be performed by attorneys in any of our offices. \n\nContact:\n            Robbins Geller Rudman & Dowd LLP \n            Ken Dolitsky\n            Michael Albert\n            655 W. Broadway, Suite 1900, San Diego, CA 92101 \n            800/851-7783 \n            info@rgrdlaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2879a30-a9fa-457e-97f6-7e2cd2528b7b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6P0Xkm","title":"INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law","author":"Globe Newswire","ticker":"IBRX","created":"2026-05-13T21:20:00.094Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller\nRudman & Dowd LLP\n(https://www.globenewswire.com/Tracker?data=dH1JBRVVUwAtXSs_rPieSwPWzxJF0xTeZdxEGs6TGiSetSaiExM7CfQxYu6Z0lNy1coB2W9KDuPmK_EgJEZ4KYbdNqTIRqvFIRvVE5vrIxE3Jp9F-MKSHSV45WLVtynIcC5LciJ8UV-BIJcXgEO3OaMY2cd0tij7xo9cjjtVEqj2H2NtQfSHFtQQvMWvFkq9)\nannounces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX)\npublicly traded securities between January 19, 2026 and March 24, 2026,\ninclusive (the “Class Period”), have until Tuesday, May 26, 2026 to seek\nappointment as lead plaintiff of the ImmunityBio class action lawsuit.\nCaptioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the\nImmunityBio class action lawsuit charges ImmunityBio as well as\nImmunityBio’s Executive Chairman with violations of the Securities Exchange\nAct of 1934.\n\nIf you suffered substantial losses and wish to serve as lead plaintiff of the\nImmunityBio class action lawsuit, please provide your information here:\n\nhttps://www.rgrdlaw.com/cases-immunitybio-class-action-lawsuit-ibrx.html\n\nYou can also contact attorneys Ken Dolitsky\n(https://www.globenewswire.com/Tracker?data=EVww4Y5UFsL1vs19Fy70IcpzR5gCXOPQ535hSYzguF7a7oyvurjj8iSQPGt4EEZSPBevfHgaDa-lhV2OxwS0ZlDN7yx1jCrT64PJkk64F-FjUohH8ShZUTVlGHUwLP0o-g7SYCSWfnNxQMQRes0glw==)\nor Michael Albert\n(https://www.globenewswire.com/Tracker?data=Za-Unon5XnbaPUaFcgReWsS9fZEYvbMC8lgSbInQbBYb7WnRkABDXC_1g5eua0uBdgnDovZeCJ8aVMnfTETPAvAQSnNBEIo5TGDaPUB5Snqo_4RDvpzmKt1dDOnAFIELSIsGUWVq9knAuNlB2-OvNwuT81XvHMTYrXxhrIyk9LI=)\nof Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.\n\nCASE ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on\ninnovating, developing, and commercializing next-generation immunotherapies.\nAccording to the complaint, ImmunityBio’s lead biologics product is Anktiva.\n\nThe ImmunityBio class action lawsuit alleges that defendants throughout the\nClass Period made false and/or misleading statements and/or failed to disclose\nthat: (i) representations that “Anktiva will allow all NMIBC patients\ntreated with Anktiva to be cancer-free for the long term, when this has not\nbeen demonstrated”; (ii) the claim that Anktiva is a cancer vaccine was\nfalse; and (iii) ImmunityBio’s Executive Chairman and Global Scientific and\nMedical Officer, defendant Dr. Patrick Soon-Shion, materially overstated\nAnktiva’s capabilities.\n\nThe ImmunityBio class action lawsuit further alleges that on March 24, 2026, a\nwarning letter (dated March 13, 2026) from the U.S. Food and Drug\nAdministration to CEO Richard Adcock was publicized, stating that a “TV ad\nand podcast misbrand[ed] Anktiva and make the distribution of the drug in\nviolation of the Federal Food, Drug, and Cosmetic Act.” The warning letter\nallegedly further stated that “[t]hese violations are concerning from a\npublic health perspective because the promotional communications create a\nmisleading impression that Anktiva, a treatment for a certain type of bladder\ncancer, can cure and even prevent all cancer.” On this news, the price of\nImmunityBio stock fell 21%, according to the complaint.\n\nTHE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of\n1995 permits any investor who purchased or acquired ImmunityBio publicly\ntraded securities during the Class Period to seek appointment as lead\nplaintiff in the ImmunityBio class action lawsuit. A lead plaintiff is\ngenerally the movant with the greatest financial interest in the relief sought\nby the putative class who is also typical and adequate of the putative class.\nA lead plaintiff acts on behalf of all other class members in directing the\nImmunityBio investor class action lawsuit. The lead plaintiff can select a law\nfirm of its choice to litigate the ImmunityBio shareholder class action\nlawsuit. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff of the ImmunityBio class action\nlawsuit.\n\nABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s\nleading law firms representing investors in securities fraud and shareholder\nrights litigation. Our Firm ranked #1 on the most recent ISS Securities Class\nAction Services Top 50 Report, recovering more than $916 million for investors\nin 2025. This marks our fourth #1 ranking in the past five years. And in those\nfive years alone, Robbins Geller recovered $8.4 billion for investors – $3.4\nbillion more than any other law firm. With 200 lawyers in 10 offices, Robbins\nGeller is one of the largest plaintiffs’ firms in the world, and the\nFirm’s attorneys have obtained many of the largest securities class action\nrecoveries in history, including the largest ever – $7.2 billion – in In\nre Enron Corp. Sec. Litig. Please visit the following page for more\ninformation:\n\nhttps://www.rgrdlaw.com/services-litigation-securities-fraud.html\n\nPast results do not guarantee future outcomes. \nServices may be performed by attorneys in any of our offices. \n\nContact:\n            Robbins Geller Rudman & Dowd LLP \n            Ken Dolitsky\n            Michael Albert\n            655 W. Broadway, Suite 1900, San Diego, CA 92101 \n            800/851-7783 \n            info@rgrdlaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2879a30-a9fa-457e-97f6-7e2cd2528b7b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-13T21:20:00.159443702Z","server_sent_at_ms":1778707200159},"received_at":"2026-05-13T21:20:00.220Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}